ASCO: Novartis makes a case for earlier Kisqali use. Will 'conservative' docs run with it?

Novartis’ breast cancer drug Kisqali so far hasn’t lived up to expectations, and the drugmaker’s hoping some strong new data in metastatic patients will help. Can the numbers actually boost the drug’s sales? Depends on how doctors decide to use them.